@article{978bbabc38fd46d09005ee52f622fe69,
title = "Detection of somatic copy number alterations in cancerusing targeted exome capture sequencing",
abstract = "The research community at large is expending considerable resources to sequence the coding region of the genomes of tumors and other human diseases using targeted exome capture (i.e., {"}whole exome sequencing{"}). The primary goal of targeted exome sequencing is to identify nonsynonymous mutations that potentially have functional consequences. Here, we demonstrate that whole-exome sequencing data can also be analyzed for comprehensively monitoring somatic copy number alterations (CNAs) by benchmarking the technique against conventional array CGH. A series of 17 matched tumor and normal tissues from patients with metastatic castrate-resistant prostate cancer was used for this assessment. We show that targeted exome sequencing reliably identifies CNAs that are common in advanced prostate cancer, such as androgen receptor (AR) gain and PTEN loss. Taken together, these data suggest that targeted exome sequencing data can be effectively leveraged for the detection of somatic CNAs in cancer.",
author = "Lonigro, {Robert J.} and Grasso, {Catherine S.} and Robinson, {Dan R.} and Xiaojun Jing and Wu, {Yi Mi} and Xuhong Cao and Quist, {Michael J.} and Tomlins, {Scott A.} and Pienta, {Kenneth J.} and Chinnaiyan, {Arul M.}",
note = "Funding Information: Address all correspondence to: Arul M. Chinnaiyan, MD, PhD, Comprehensive Cancer Center, University of Michigan Medical School, 1400 E Medical Center Dr, 5316 CCGC, Ann Arbor, MI 48109-0602. E-mail: arul@umich.edu 1This work was supported in part by the National Institutes of Health (NIH) Specialized Program of Research Excellence (P50 CA69568) and the Early Detection Research Network (U01 CA111275). A.M.C. is supported by the Howard Hughes Medical Institute, the Prostate Cancer Foundation, the Taubman Research Institute, the Doris Duke Foundation, and the American Cancer Society as a clinical research professor. K.J.P. is supported by the Prostate Cancer Foundation, the Taubman Research Institute, and the American Cancer Society as a clinical research professor (NIH 1 PO1 CA093900 and 1 U01CA143055). 2This article refers to supplementary materials, which are designated by Figures W1 to W3 and Tables W1 to W4 and are available online at www.neoplasia.com. 3Dr Chinnaiyan is an investigator for Howard Hughes Medical Institute, an American Cancer Society professor, an S. P. Hicks Endowed Professor of Pathology, and a professor of pathology and urology. Received 2 September 2011; Revised 2 September 2011; Accepted 28 September 2011 Copyright {\textcopyright} 2011 Neoplasia Press, Inc. All rights reserved 1522-8002/11/$25.00 DOI 10.1593/neo.111252 Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",
year = "2011",
month = nov,
doi = "10.1593/neo.111252",
language = "English (US)",
volume = "13",
pages = "1019--1025",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "11",
}